Sacituzumab Govitecan In TNBC

Conditions:   Invasive Breast Cancer;   Triple Negative Breast Cancer;   ER-Negative Breast Cancer;   PR-Negative Breast Cancer;   HER2-negative Breast Cancer Intervention:   Drug: Sacituzumab Govitecan Sponsors:   Aditya Bardia;   Immunomedics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials